Lonza to expand manufacturing drug substance for COVID-19 Vaccine Moderna
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of COVID-19
Subscribe To Our Newsletter & Stay Updated